Skip to content

Individual and placement support for alcohol and drug dependence

Effectiveness and cost-effectiveness of employment support during treatment for drug and alcohol dependence: the Individual Placement and Support for Alcohol and Drug dependence (IPS-AD) trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN24159790
Enrollment
2400
Registered
2018-02-01
Start date
2018-05-08
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult, unemployed, in treatment for drug and/or alcohol dependence Mental and Behavioural Disorders

Interventions

Randomisation is individual, allocation ratio 1:1. This is accessed via a secure website and created and independently managed by the King’s College London Clinical Trials Unit. 1. Intervention: Empl

Sponsors

Public Health England
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years 2. Enrolled in treatment for drug or alcohol use disorder for at least 14 days with current diagnosis of a specified drug and/or alcohol use disorder 3. Unemployed or inactive at study screening visit for at least 6 months with declared wish to obtain open job market employment 4. Able to attend the community addiction clinic as required in the protocol 5. Able to communicate (verbal and written English) at a level required to engage with a psychosocial intervention 6. Able to provide personal National Insurance number to facilitate data linkage

Exclusion criteria

Exclusion criteria: 1. Currently receiving detoxification treatment for drug or alcohol withdrawal 2. Clinically significant (or otherwise uncontrolled) severe mental health, intellectual disability, organic brain disease or dementia, or physical disability that is judged by the local clinical lead to prevent the person accepting IPS 3. Suicide planning (past month) or suicide attempt (past 6 months) 4. Current legal proceedings which are likely to result in imprisonment 5. Current enrolment in an IPS trial, or within the past 6 months 6. Previously enrolled in, and dropped out of, the IPS-AD trial

Design outcomes

Primary

MeasureTime frame
At least 1 day of employment in the open market during an 18-months follow-up from the time of enrolment in the trial. This will be measured via matching administrative datasets at 18 months after enrolment.

Secondary

MeasureTime frame
1. Employment: 1.1. Total time worked (days/hours), measured via matching administrative datasets at 18 months after enrolment 1.2. Time to first employment during follow-up, measured via matching administrative datasets at 18 months after enrolment 1.3. Number of appointments (individual jobs attained), measured via matching administrative datasets at 18 months after enrolment 1.4. Duration of longest employment (tenure), measured via matching administrative datasets at 18 months after enrolment 1.5. Continuous employment for at least 13 weeks during follow-up (used by the UK Office of National Statistics for employment statistics and captures sustained employment), measured via matching administrative datasets at 18 months after enrolment The secondary employment outcome measures will also be monitored via data linkage with the LMS and HMRC data held by DWP. 2. Personal, vocational, social functioning and support: 2.1. Job search self-efficacy, measured using the Job Search Self-Efficacy-Behaviour (JSSE-B) scale at enrolment, 6, 12 and 18 months 2.2. Clinical, health and social functioning (i.e. use of illicit substances; consumption of alcohol; non-medical drug injecting behaviour; psychological and physical health and well-being via TOP; DSM-5 remission status), measured using SCID-CV at enrolment, 6, 12 and 18 months 2.3. Drug and alcohol treatment: total time in treatment, number of treatment journeys, treatment status at end of follow-up (in treatment, left: successfully; left: unsuccessfully), measured via analysis of the National Drug Treatment Monitoring System (NDTMS) at 18 months after enrolment The clinical, health and social functioning outcomes will be collected and monitored using the National Drug Treatment Monitoring System (NDTMS), using data that is already routinely collected by PHE on all individuals in substance misuse treatment. 3. QALY/healthcare/societal cost-related: 3.1. Health-related quality of life (EQ5D-5L), measured via analys

Countries

England, United Kingdom

Contacts

Public ContactPaul Anders
Paul.anders@dhsc.gov.uk+44 (0)20 3682 0536

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 28, 2026